Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.

Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.

Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.

Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.

Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.

Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.

Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.

Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.

Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.

Abstract: Pharmaceutical formulations comprising docetaxel or a pharmaceutically acceptable salt thereof, one or more solubilizers, ?-lipoic acid, TPGS, one or more hydrotropes, and optionally one or more agents having a pKa of about 3 to about 6. The pharmaceutical formulations are stable and substantially free of excipients that can cause severe side effects and maintains chemical stability during storage. The pharmaceutical formulations are ready to be combined with an infusion solution for administration to patients in need thereof. Methods of treating patients in need thereof comprise administering the pharmaceutical formulations combined with an infusion solution.

Abstract: A storage stable aqueous solution of amifostine at a pH of at least 10.0, in an amifostine concentration of about 50 to about 250 mg/l, which formulation is storage stable under refrigerated conditions.

Abstract: Formulations comprising docetaxel or a salt thereof in combination with ?-lipoic acid and/or dihydrolipoic acid and/or salts thereof in narrow concentration ranges have improved stability as concentrate liquid formulations and permit longer times between dilution from higher concentrations through completion of infusions prepared therefrom allowing for lesser waste and more efficient use of personnel in infusion preparation.

Abstract: An aqueous formulation of argatroban and of related compounds is disclosed along with a reconstitutable formulation, each of which is substantially, if not totally alcohol free. The formulations are also substantially free, if not totally free, of mono-, di-, and oligo-saccharides. An especially preferred embodiment is a ready-to-use 1 mg/ml injectable dosage form having argatroban, lactobionic acid, and methionine.

Abstract: Lyophilizates containing docetaxel and the use thereof in preparing concentrated liquid formulations, and ready to use formulations for injection, as well as such concentrates and ready to use formulations themselves are disclosed in which Tween surfactants are avoided so that hypersensitivity reactions to Tween surfactants can be avoided and docetaxel can be administered at higher doses and/or for longer periods of time and/or for additional treatment cycles.

Abstract: Pharmaceutical formulations comprising docetaxel or a pharmaceutically acceptable salt thereof, one or more solubilizers, ?-lipoic acid, TPGS, one or more hydrotropes, and optionally one or more agents having a pKa of about 3 to about 6. The pharmaceutical formulations are stable and substantially free of excipients that can cause severe side effects and maintains chemical stability during storage. The pharmaceutical formulations are ready to be combined with an infusion solution for administration to patients in need thereof. Methods of treating patients in need thereof comprise administering the pharmaceutical formulations combined with an infusion solution.

Abstract: A lyophilization process which comprises dissolving a material in one or more solvents for said material to form a solution; forcing said material at least partially out of solution by combining the solution and a non-solvent for the material, which non-solvent is miscible with the solvent or solvents used and wherein said non-solvent is volatilizable under freeze-drying conditions. In addition, for hydrophobic and/or lipophilic materials, the anti-solvent can be omitted, and the solution of the material in the solvent can be subjected directly to freeze drying. The lyophilizates can then be reconstituted with typical aqueous diluent in the case of hydrophilic materials. Hydrophobic and or lipophilic materials can be initially reconstituted with propylene glycol and/or polyethyleneglycol to form a high concentration solution therein and this is further diluted for use with a diluent of Intralipid, plasma, serum, or even whole blood.

Abstract: Formulations comprising docetaxel or a salt thereof in combination with ?-lipoic acid and/or dihydrolipoic acid and/or salts thereof in narrow concentration ranges have improved stability as concentrate liquid formulations and permit longer times between dilution from higher concentrations through completion of infusions prepared therefrom allowing for lesser waste and more efficient use of personnel in infusion preparation.

Abstract: Docetaxel containing formulations having TPGS and being substantially free or totally free of polysorbate surfactants are disclosed wherein stability is enhanced and hypersensitivity reactions are reduced.

Abstract: Co-therapy of an anti-obesity agent, a statin, is disclosed along with fixed combinations thereof. Atorvastatin and orlistat are preferred as the various components.

Abstract: An aqueous formulation of argatroban and of related compounds is disclosed along with a reconstitutable formulation, each of which is substantially, if not totally alcohol free. The formulations are also substantially free, if not totally free, of mono-, di-, and oligo-saccharides. An especially preferred embodiment is a ready-to-administer 1 mg/ml injectable dosage form having argatroban, lactobionic acid, and methionine.